
doi: 10.1271/bbb.69.829
pmid: 15849424
A double-blind comparative study was conducted on cedar pollinosis patients in order to evaluate the treatment efficacy of apple polyphenol (Ap). Ap was administered (500 mg) once daily for 12 weeks, starting about 2 weeks prior to cedar pollen dispersion. Pollinosis symptoms during the study were evaluated according to the classification in the guidelines for allergic rhinitis diagnosis and treatment. The results show that the sneezing score was significantly lower for the Ap group than with the placebo group during the early period of pollen dispersion and during the main dispersion period. In addition, no adverse reactions were induced by Ap during the study. These results suggest that Ap may alleviate the symptoms of cedar pollinosis.
Flavonoids, apple polyphenol, Rhinitis, Allergic, Perennial, Time Factors, Polyphenols, mast cells, histamine, Sneezing, cedar pollinosis, Double-Blind Method, Japan, Phenols, Malus, Anti-Allergic Agents, Humans, Pollen, Cedrus
Flavonoids, apple polyphenol, Rhinitis, Allergic, Perennial, Time Factors, Polyphenols, mast cells, histamine, Sneezing, cedar pollinosis, Double-Blind Method, Japan, Phenols, Malus, Anti-Allergic Agents, Humans, Pollen, Cedrus
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 31 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
